SCHEMBL26928461

SCHEMBL26928461

Clc1nccc2cc(N3CCCC3)ccc12

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TERT O14746 3/20 0.49
HSD17B10 Q99714 2/20 0.44
PKM P14618 1/20 0.44
ALOX15 P16050 1/20 0.44
CASP1 P29466 1/20 0.44
CHKA P35790 2/20 0.43
IP6K1 Q92551 3/20 0.41
HRH4 Q9H3N8 1/20 0.41
C1S P09871 1/20 0.41
MAP4K4 O95819 1/20 0.40
PRKDC P78527 2/20 0.40
ALDH1A1 P00352 1/20 0.39
MAPT P10636 1/20 0.39
RAB9A P51151 1/20 0.39
IP6K3 Q96PC2 1/20 0.39
CCNC P24863 1/20 0.39
CDK8 P49336 1/20 0.39
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14304006 0.86 PRKDC (0.46) ALOX15CASP1PRKDCMAPTRAB9A
SCHEMBL14038465 0.76 LMNA (0.33) C1SMAPTMEN1KMT2A
SCHEMBL1624366 0.76 WNT3A (0.41) PRKDCKMT2A
SCHEMBL1624364 0.76 WNT3A (0.41) PRKDCKMT2A
SCHEMBL12277506 0.75 TERT (0.57) TERTHSD17B10PKMALOX15IP6K1
SCHEMBL12260005 0.75 TERT (0.57) TERTHSD17B10PKMALOX15IP6K1
Hydrochloric Acid SCHEMBL31587312 0.74 DRD4 (0.47) ALDH1A1MAPTMEN1KMT2A
SCHEMBL26928541 0.74 MAPK1 (0.41) TERTALOX15ALDH1A1MAPTMEN1
SCHEMBL1536322 0.72 NOTUM (0.51) ALDH1A1MAPTMEN1KMT2A
SCHEMBL24126771 0.72 CHKA (0.52) TERTHSD17B10PKMALOX15CASP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4536356-A1 PYRIDINAMINE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS Xenon Pharmaceuticals Inc. (CA) 2025-04-16 EP disclosed
US-20240101531-A1 PYRIDINAMINE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS XENON PHARMACEUTICALS INC. (CA) 2024-03-28 US disclosed
WO-2023239729-A1 PYRIDINAMINE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS XENON PHARMACEUTICALS INC. (CA) 2023-12-14 WO disclosed
WO-2023239729-A1 PYRIDINAMINE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS XENON PHARMACEUTICALS INC. (CA) 2023-12-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240101531-A1 PYRIDINAMINE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS KCNA1, KCNB1, KCNB2 TERT 3896/4885HSD17B10 3551/4885PKM 93/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.